A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy
Latest Information Update: 06 Sep 2021
At a glance
- Drugs Vildagliptin (Primary) ; Gliclazide; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 08 Nov 2012 Planned number of patients changed from 588 to 1000.
- 23 Jun 2010 Additional lead trial centres and trial investigators identified as reported by Clinical Trials Registry - India record.
- 23 Jun 2010 New source identified and integrated (Clinical Trials Registry - India).